NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board
Vancouver, Canada. October 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field […]
Expanding the Status Quo – Diversifying Mainstream Media
By Codi Darnell October 19, 2021 It’s October – the month of pumpkin spice, Canadian Thanksgiving and Halloween. While pumpkin spice is the highlight for me, for the three kids in our house, it’s Halloween. And the search for the perfect costume started early. It was possibly still September when I ventured onto Party City’s […]
NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile
Vancouver, Canada. October 18, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a positive update on its Phase 1 program with NVG-291 in healthy volunteers at the 146th Annual Meeting of the American Neurological Association. […]
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
Cincinnati, Ohio. October 4, 2021 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its release of the Fiscal Year 2022 National Defense […]
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
Vancouver, Canada. September 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. (“Imeka”), currently the only neuroimaging company that combines artificial intelligence and diffusion imaging […]
The Outdoor Diaries: Climbing Mountains and Removing Barriers with Nick Allen
By Codi Darnell September 28, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. Motivation comes in many forms. What […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. September 14, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of $2.10 per share […]
A Glimpse into the Paralympics
By Codi DarnellSeptember 14, 2021 The Olympic rings – it is an easily identifiable symbol that signifies the continents coming together to compete at the Olympic Games. But this iconic image says more than that. Without using any words, the interlocking circles are known worldwide to represent strength, competition, and athleticism at the highest level. […]
NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, Canada. September 12, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021. The presentation will […]
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, Canada. September 10, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders (“AGM”) held on September 9, 2021. “We are very pleased […]
